Free Trial

Avalo Therapeutics (AVTX) Competitors

Avalo Therapeutics logo
$11.70 -0.13 (-1.10%)
Closing price 09/22/2025 04:00 PM Eastern
Extended Trading
$11.56 -0.15 (-1.24%)
As of 09/22/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AVTX vs. PRME, IVA, OLMA, AQST, CMPS, CMPX, BCYC, KOD, ETON, and ARCT

Should you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Prime Medicine (PRME), Inventiva (IVA), Olema Pharmaceuticals (OLMA), Aquestive Therapeutics (AQST), COMPASS Pathways (CMPS), Compass Therapeutics (CMPX), Bicycle Therapeutics (BCYC), Kodiak Sciences (KOD), Eton Pharmaceuticals (ETON), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry.

Avalo Therapeutics vs. Its Competitors

Avalo Therapeutics (NASDAQ:AVTX) and Prime Medicine (NASDAQ:PRME) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Avalo Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,016.83%. Avalo Therapeutics' return on equity of -48.48% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Avalo TherapeuticsN/A -48.48% -35.94%
Prime Medicine -4,016.83%-156.16%-64.41%

Avalo Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.39, meaning that its stock price is 139% more volatile than the S&P 500.

Avalo Therapeutics has higher earnings, but lower revenue than Prime Medicine.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avalo Therapeutics$440K349.67-$35.13MN/AN/A
Prime Medicine$2.98M225.34-$195.88M-$1.56-3.20

Avalo Therapeutics currently has a consensus price target of $31.67, suggesting a potential upside of 170.66%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Avalo Therapeutics is more favorable than Prime Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalo Therapeutics
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00
Prime Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 0.3% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 22.7% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Avalo Therapeutics had 3 more articles in the media than Prime Medicine. MarketBeat recorded 11 mentions for Avalo Therapeutics and 8 mentions for Prime Medicine. Avalo Therapeutics' average media sentiment score of 0.72 beat Prime Medicine's score of 0.24 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avalo Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Prime Medicine
1 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Avalo Therapeutics beats Prime Medicine on 11 of the 14 factors compared between the two stocks.

Get Avalo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVTX vs. The Competition

MetricAvalo TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$155.59M$2.57B$5.80B$10.46B
Dividend YieldN/A55.05%5.61%4.57%
P/E RatioN/A23.06348.5626.86
Price / Sales349.67712.83549.90125.65
Price / CashN/A27.8326.0131.15
Price / Book0.915.3615.536.50
Net Income-$35.13M$32.95M$3.29B$271.25M
7 Day Performance15.38%3.96%200.87%3.69%
1 Month Performance18.42%5.27%184.38%8.07%
1 Year Performance20.37%-0.72%325.51%29.65%

Avalo Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVTX
Avalo Therapeutics
3.9594 of 5 stars
$11.70
-1.1%
$31.67
+170.7%
+20.4%$155.59M$440K0.0040Gap Down
PRME
Prime Medicine
0.4801 of 5 stars
$4.01
-1.5%
N/AN/A$547.72M$2.98M0.00N/A
IVA
Inventiva
3.0857 of 5 stars
$5.31
-5.3%
$14.83
+179.3%
+193.7%$536.67M$9.95M0.00100Upcoming Earnings
Gap Up
OLMA
Olema Pharmaceuticals
2.7404 of 5 stars
$8.00
+3.0%
$24.00
+200.0%
-38.8%$533.29MN/A-4.0470
AQST
Aquestive Therapeutics
1.8829 of 5 stars
$5.14
+1.8%
$10.29
+100.1%
+1.6%$503.61M$44.13M-7.34160News Coverage
Options Volume
CMPS
COMPASS Pathways
2.9724 of 5 stars
$5.14
-1.2%
$16.29
+216.8%
-30.5%$498.89MN/A-2.79120Positive News
CMPX
Compass Therapeutics
1.9106 of 5 stars
$3.69
+3.4%
$13.88
+276.0%
+110.2%$493.67M$850K-8.2020
BCYC
Bicycle Therapeutics
3.1037 of 5 stars
$6.86
-3.0%
$22.22
+223.9%
-71.9%$490M$19.28M-1.95240
KOD
Kodiak Sciences
2.6225 of 5 stars
$9.35
+1.1%
$11.75
+25.7%
+468.6%$488.60MN/A-2.4690News Coverage
Analyst Forecast
Gap Up
ETON
Eton Pharmaceuticals
2.1652 of 5 stars
$17.78
+0.7%
$29.67
+66.9%
+238.9%$473.34M$58.18M-111.1320News Coverage
Positive News
ARCT
Arcturus Therapeutics
2.9377 of 5 stars
$18.13
+4.7%
$50.57
+178.9%
+2.0%$470.32M$152.31M-8.13180Positive News

Related Companies and Tools


This page (NASDAQ:AVTX) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners